# FBXW7
## Overview
FBXW7 mutations are found in a range of lymphoid malignancies, including B-cell lymphomas. These mutations often include missense mutations, deletions, frameshift mutations and splice-site mutations. Overall, these mutations are relatively rare in DLBCL and occur more frequently in other solid tumors as well as T-cell acute lymphocytic leukemia.<sup>1</sup> The most commonly observed mutations in those cancers are the hot spots R465 and R479.<sup>1</sup> In leukemias, FBXW7 mutations enhance the activity of leukemia-initiating cells by stabilizing oncogenic MYC.<sup>2</sup> Whether they have this role in DLBCL remains to be determined. 

## Relevance tier by entity

|Entity|Tier|Description               |
|:------:|:----:|--------------------------|
|DLBCL |1   |high-confidence DLBCL gene|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source        |frequency (%)|
|:------:|:--------------:|:-------------:|
|DLBCL |GAMBL genomes |2.10         |
|DLBCL |Schmitz cohort|2.98         |
|DLBCL |Reddy cohort  |1.30         |
|DLBCL |Chapuy cohort |1.71         |

## Mutation pattern and selective pressure estimates

|Entity|aSHM|Significant selection|dN/dS (missense)|dN/dS (nonsense)|
|:------:|:----:|:---------------------:|:----------------:|:----------------:|
|BL    |No  |No                   |3.846           | 0.000          |
|DLBCL |No  |No                   |2.734           |10.734          |
|FL    |No  |No                   |2.987           |22.593          |



View coding variants in ProteinPaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/FBXW7_protein.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/FBXW7_protein_hg38.html)

![image](images/proteinpaint/FBXW7_NM_033632.svg)

View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/FBXW7.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/FBXW7_hg38.html)

![image](images/proteinpaint/FBXW7.svg)

## References
1. *Akhoondi, S., Sun, D., Lehr, N., Apostolidou, S., Klotz, K., Maljukova, A., Cepeda, D., Fiegl, H., Dafou, D., Marth, C., Mueller-Holzner, E., Corcoran, M., Dagnell, M., Nejad, S., Nayer, B., Zali, M., Hansson, J., Egyhazi, S., Petersson, F., Sangfelt, P., Nordgren, H., Grandér, D., Reed, S., Widschwendter, M., Sangfelt, O., & Spruck, C. (2007). FBXW7/hCDC4 is a general tumor suppressor in human cancer.. Cancer research, 67 19, 9006-12 . https://doi.org/10.1158/0008-5472.CAN-07-1320.*
2. *King, B., Trimarchi, T., Reavie, L., Xu, L., Mullenders, J., Ntziachristos, P., Aranda-Orgilles, B., Pérez-García, A., Shi, J., Vakoc, C., Sandy, P., Shen, S., Ferrando, A., & Aifantis, I. (2013). The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability. Cell, 153, 1552-1566. https://doi.org/10.1016/j.cell.2013.05.041.*
## FBXW7 Expression
![image](images/gene_expression/FBXW7_by_pathology.svg)
<!-- ORIGIN: zhangGeneticHeterogeneityDiffuse2013 -->
<!-- DLBCL: zhangGeneticHeterogeneityDiffuse2013 -->
